In Reply It is important to note that we made neither of the assumptions attributed to us. We did not assume, nor state or imply, that all pharmacogenomic (Pgen) test panels are the same or that Pgen testing is incompatible with protocol-based care. First, we explained the scientific evidence behind our conclusion that no current panel of genes should be expected to have clinical utility for the treatment of major depressive disorder (MDD). Second, we discussed why published clinical studies provide inadequate evidence to justify the use of current Pgen tests.1 Other independent experts confirm these points, documenting both the lack of scientific evidence behind the panels2 and the inadequacy of studies cited as supporting the clinical use of Pgen tests.3,4 Unfortunately, instead of better studies, larger studies are now being reported. No study has included the needed blinding of all participants or proper treatment comparison groups.1 Even with designs favoring Pgen tests, patients with Pgen-guided treatment did not have clearly better outcomes.1,3,4 These findings suggest currently offered Pgen testing has no clinical value in MDD.
Zubenko GS, Sommer BR, Cohen BM. Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care—Reply. JAMA Psychiatry. 2018;75(10):1090–1091. doi:10.1001/jamapsychiatry.2018.2355
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: